Thursday, 15 November 2018

Sun Pharma’s Aggrenox gets USFDA nod

24 August 2018 | News

This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox (Aspirin/Dipyridamole). Aggrenox and its generics are estimated to have US sales of ~$230mn in the US

Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox.

 Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.

Aggrenox and its generics are estimated to have US sales of approximately $230mn in the US and with the lower competition, Sun pharma expect to make $8-10mn/annum from this drug.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!




Survey Box

Will the health insurance sector receive benefits from Ayushman Bharat?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls